The latest findings underline the case for personalized medicine, or tailoring drugs to the genetic make-up of (individual) patients. Scientists at the Sanger Institute last month also produced genetic "maps" identifying thousands of genetic mutations behind melanoma (skin) cancer and lung cancer. Several personalized drugs are already used in cancer, including Roche's Herceptin for (breast) cancer and AstraZeneca's Iressa for lung cancer.
相关阅读:
医学英语口语课程
医学英语水平免费测试